Observational study shows effectiveness and safety of combination therapy in medically complex Crohn’s disease, suggesting a new treatment option.
Lay Summary This study presents real-world observational data of the combination of risankizumab and upadacitinib and demonstrates the safety and effectiveness of this unique combination strategy for the treatment of medically complex Crohn’s disease.
No takes yet. Share an insight, caveat, or question.
Fear et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: